Trial of Dasatinib in Advanced Sarcomas

Trial of Dasatinib in Advanced Sarcomas

Gastrointestinal Stromal Tumor

Ongoing, but not recruiting

2

Start Date 05/01/2007

Age of Trial (yrs) 17.6

Gleevec-resistant

KIT/PDGFRA inhibitor + SRC inhibitor

Block KIT + Block KIT Signal Path

Specifically GIST plus other cancers

SARC009

SARC Bristol-Myers Squibb

Kathleen Granlund kegranlund@sarctrials.org 734-930-7607

Oral

Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle.

AS OF 2/2/2010 GIST PATIENTS ARE NO LONGER ELIGIBLE FOR THIS TRIAL


Subjects will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6 months and approximately every 3 months thereafter while on treatment.

A blood sample for collection of specimens with which to later study serum level of Dasatinib and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after the start of treatment.

Central collection of archival tumor with which to later study the frequency of expression and/or mutation of kinases inhibited by dasatinib will occur.

Subjects will be followed for approximately every 3 months until 2 years from registration and then approximately yearly until 5 years from registration.